|
|
||||||||
1Division of Cardiology, Department of Pediatrics, University of Washington School of Medicine, and 2Children's Hospital and Regional Medical Center, Seattle, Washington
Submitted 19 August 2004 ; accepted in final form 20 December 2004
Thyroid acting through ligand binding to nuclear receptors modifies myocardial respiratory kinetics and oxidative phosphorylation in the heart. Direct nongenomic action of thyroid hormone on high-energy phosphate concentrations and respiratory kinetics has never been proven in vivo but might be responsible for observed changes in oxygen utilization efficiency immediately after triiodothyronine (T3) administration. We tested the hypothesis that T3 directly and rapidly modifies myocardial high-energy phosphate concentrations and phosphorylation potential in vivo. Anesthetized sheep (age 2840 days) thyroidectomized shortly after birth (Thy) and euthyroid age-matched controls (Con) underwent median sternotomy and received T3 infusion (0.8 µg/kg), followed by epinephrine infusion to increase myocardial oxygen consumption (M
O2). 31P magnetic resonance spectra were monitored via a surface coil over the left ventricle. T3 increased phosphocreatine (PCr)/ATP and decreased ADP in Thy animals without causing a change in M
O2. T3 produced no changes in high-energy phosphates in Con animals. T3 did not modify the PCr/ATP or ADP response to epinephrine and elevation in M
O2 in either group. Cardiac mitochondria isolated from Thy and Con animals showed no change in respiratory rate or ADP/ATP exchange efficiency after T3 incubation. T3 infusion in a hypothyroid state decreases ADP concentration, thereby altering the equilibrium between phosphorylation potential and myocardial respiratory rate. These T3-induced effects are not due to changes in ADP/ATP exchange efficiency through action at the adenine nucleotide translocator but may be due to T3 mediation of substrate utilization, confirmed in other models.
adenine nucleotide translocator; myocardial energy metabolism; substrate oxidation
This article has been cited by other articles:
![]() |
O. M. Hyyti, A. K. Olson, M. Ge, X.-H. Ning, N. E. Buroker, Y. Chung, T. Jue, and M. A. Portman Cardioselective dominant-negative thyroid hormone receptor ({Delta}337T) modulates myocardial metabolism and contractile efficiency Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E420 - E427. [Abstract] [Full Text] [PDF] |
||||
![]() |
N. E. Buroker, M. E. Young, C. Wei, K. Serikawa, M. Ge, X.-H. Ning, and M. A. Portman The dominant negative thyroid hormone receptor beta-mutant {Delta}337T alters PPAR{alpha} signaling in heart Am J Physiol Endocrinol Metab, February 1, 2007; 292(2): E453 - E460. [Abstract] [Full Text] [PDF] |
||||
![]() |
O. M. Hyyti, X.-H. Ning, N. E. Buroker, M. Ge, and M. A. Portman Thyroid hormone controls myocardial substrate metabolism through nuclear receptor-mediated and rapid posttranscriptional mechanisms Am J Physiol Endocrinol Metab, February 1, 2006; 290(2): E372 - E379. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. D. McClure, M. E. Young, H. Taegtmeyer, X.-H. Ning, N. E. Buroker, J. Lopez-Guisa, and M. A. Portman Thyroid hormone interacts with PPAR{alpha} and PGC-1 during mitochondrial maturation in sheep heart Am J Physiol Heart Circ Physiol, November 1, 2005; 289(5): H2258 - H2264. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |